Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

198.07 

-0.59 -0.3%

as of Apr 09 '21

52 Week Range:

145.11 223.62


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 11.12
11.60
12.52
13.87
16.82
15.71
18.19
20.85
24.73
28.02
32.41
growth rate 4.3% 7.9% 10.8% 21.3% -6.6% 15.8% 14.6% 18.6% 13.3% 15.7%
Earnings BIT 92.72
29.00
69.20
122.20
211.15
281.54
319.85
346.09
385.85
433.41
409.59
growth rate -68.7% 138.6% 76.6% 72.8% 33.3% 13.6% 8.2% 11.5% 12.3% -5.5%
Avg.PE 15.24
45.66
30.30
24.45
24.64
18.12
17.95
22.13
23.36
22.60
30.04
growth rate 199.6% -33.6% -19.3% 0.8% -26.5% -0.9% 23.3% 5.6% -3.3% 32.9%
ROA 9.37
2.31
4.95
7.78
11.61
14.75
14.79
14.17
14.34
14.22
10.48
growth rate -75.4% 114.3% 57.2% 49.2% 27.1% 0.3% -4.2% 1.2% -0.8% -26.3%
ROE 14.02
3.39
7.72
12.35
18.54
27.96
30.70
26.35
25.35
25.16
19.16
growth rate -75.8% 127.7% 60.0% 50.1% 50.8% 9.8% -14.2% -3.8% -0.8% -23.9%
ROIC 13.92
3.44
7.81
12.38
18.50
20.04
22.62
20.49
20.37
18.28
15.67
growth rate -75.3% 127.0% 58.5% 49.4% 8.3% 12.9% -9.4% -0.6% -10.3% -14.3%
Cur. Ratio 2.32
1.83
1.61
1.70
1.52
1.51
1.94
1.95
2.18
1.44
1.87
growth rate -21.1% -12.0% 5.6% -10.6% -0.7% 28.5% 0.5% 11.8% -33.9% 29.9%
Quick Ratio 1.81
1.30
1.50
1.60
1.42
1.45
1.87
1.88
2.12
1.40
1.82
growth rate -28.2% 15.4% 6.7% -11.3% 2.1% 29.0% 0.5% 12.8% -34.0% 30.0%
Leverage 1.42
1.52
1.59
1.58
1.60
2.25
1.93
1.80
1.74
1.80
1.86
growth rate 7.0% 4.6% -0.6% 1.3% 40.6% -14.2% -6.7% -3.3% 3.5% 3.3%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 164.90
363.97
285.40
342.60
550.33
636.71
662.20
706.19
837.62
1,013.53
1,207.47
growth rate 120.7% -21.6% 20.0% 60.6% 15.7% 4.0% 6.6% 18.6% 21.0% 19.1%
Acct.Payable 160.10
8.10
4.60
2.79
7.02
8.70
60.38
46.53
55.58
101.55
growth rate -94.9% -43.2% -39.3% 151.4% 23.9% 594.3% -22.9% 19.4% 82.7%
Cur.Assets 579.70
559.57
663.70
853.40
819.51
862.74
957.96
1,101.02
1,330.18
1,624.98
2,102.98
growth rate -3.5% 18.6% 28.6% -4.0% 5.3% 11.0% 14.9% 20.8% 22.2% 29.4%
Total Assets 949.50
1,027.52
1,202.10
1,442.50
1,528.85
1,717.21
1,825.84
2,146.62
2,354.26
2,907.51
3,435.61
growth rate 8.2% 17.0% 20.0% 6.0% 12.3% 6.3% 17.6% 9.7% 23.5% 18.2%
Cash 255.70
119.24
114.00
182.50
118.90
103.91
192.54
282.86
395.85
520.31
840.31
growth rate -53.4% -4.4% 60.1% -34.9% -12.6% 85.3% 46.9% 40.0% 31.4% 61.5%
Inventory 0.00
0.00
3.00
2.00
1.70
1.80
2.40
2.20
2.30
3.20
4.80
growth rate -33.3% -15.0% 5.9% 33.3% -8.3% 4.6% 39.1% 50.0%
Cur.Liabilities 250.30
306.06
413.40
501.20
538.36
571.80
494.41
566.06
610.62
1,131.25
1,123.94
growth rate 22.3% 35.1% 21.2% 7.4% 6.2% -13.5% 14.5% 7.9% 85.3% -0.7%
Liabilities 279.50
345.97
447.50
531.90
578.64
954.11
880.67
955.62
999.97
1,249.95
1,585.37
growth rate 23.8% 29.4% 18.9% 8.8% 64.9% -7.7% 8.5% 4.6% 25.0% 26.8%
LT Debt 0.00
0.00
0.00
0.00
0.00
348.31
348.51
348.89
349.26
348.48
growth rate 0.1% 0.1% 0.1% -0.1%
Equity 670.00
681.54
754.60
910.60
950.21
763.10
945.17
1,191.00
1,354.28
1,618.06
1,850.24
growth rate 1.7% 10.7% 20.7% 4.4% -19.7% 23.9% 26.0% 13.7% 19.5% 14.4%
Common Shares 61.00
61.00
60.00
62.00
63.00
60.00
56.00
55.00
55.00
54.00
53.00
growth rate 0.0% -1.6% 3.3% 1.6% -4.8% -6.7% -1.8% 0.0% -1.8% -1.9%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 31.00
35.28
31.00
29.49
32.78
49.73
42.60
44.72
48.40
50.65
51.06
growth rate 13.8% -12.1% -4.9% 11.2% 51.7% -14.3% 5.0% 8.2% 4.6% 0.8%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 87.40
20.19
113.40
221.20
169.04
279.07
259.20
383.08
268.64
412.54
568.04
growth rate -76.9% 461.6% 95.1% -23.6% 65.1% -7.1% 47.8% -29.9% 53.6% 37.7%
FCF per Share 0.93
-0.28
1.37
1.69
2.58
3.11
3.71
6.71
4.81
5.27
8.60
growth rate -100.0% 100.0% 23.4% 52.7% 20.5% 19.3% 80.9% -28.3% 9.6% 63.2%
Sale Purchase of Stock -4.53
-15.90
0.00
22.27
21.00
10.18
-119.28
-128.96
-146.93
growth rate 0.0% 0.0% -5.7% -51.5% -100.0% 0.0% 0.0%
FCF 56.00
-15.00
83.00
192.00
137.00
230.00
217.00
338.00
220.00
362.00
517.00
growth rate -100.0% 100.0% 131.3% -28.7% 67.9% -5.7% 55.8% -34.9% 64.6% 42.8%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 1,263.10
945.73
1,504.00
1,784.30
1,503.32
1,574.98
1,666.49
1,758.44
2,595.78
2,805.84
2,797.29
growth rate -25.1% 59.0% 18.6% -15.8% 4.8% 5.8% 5.5% 47.6% 8.1% -0.3%
Op.Income 92.10
22.88
55.40
102.80
211.15
281.54
319.85
346.09
385.85
433.41
409.59
growth rate -75.2% 142.1% 85.6% 105.4% 33.3% 13.6% 8.2% 11.5% 12.3% -5.5%
IBT 92.70
29.00
67.20
120.90
202.72
278.85
300.17
328.06
364.61
426.99
380.84
growth rate -68.7% 131.8% 79.9% 67.7% 37.6% 7.7% 9.3% 11.1% 17.1% -10.8%
Net Income 87.10
22.88
55.40
102.80
172.47
239.54
262.18
281.49
322.66
373.99
332.33
growth rate -73.7% 142.1% 85.6% 67.8% 38.9% 9.5% 7.4% 14.6% 15.9% -11.1%
EPS 1.44
0.37
0.92
1.65
2.73
3.97
4.65
5.13
5.89
6.79
6.15
growth rate -74.3% 148.7% 79.4% 65.5% 45.4% 17.1% 10.3% 14.8% 15.3% -9.4%
Gross Profit 358.70
333.81
397.10
1,336.10
600.15
666.00
705.15
731.13
777.56
834.20
819.91
growth rate -6.9% 19.0% 236.5% -55.1% 11.0% 5.9% 3.7% 6.4% 7.3% -1.7%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT 113.48
106.29
75.04
108.40
119.86
growth rate -6.3% -29.4% 44.5% 10.6%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 1,013.53
1,029.48
946.46
1,018.38
1,207.47
growth rate 1.6% -8.1% 7.6% 18.6%
Acct.Payable 55.58
23.33
32.72
28.70
101.55
growth rate -58.0% 40.3% -12.3% 253.8%
Cur.Assets 1,624.98
1,555.56
1,578.40
1,771.06
2,102.98
growth rate -4.3% 1.5% 12.2% 18.7%
Total Assets 2,907.51
2,841.33
2,858.72
3,065.30
3,435.61
growth rate -2.3% 0.6% 7.2% 12.1%
Cash 520.31
482.37
592.10
708.00
840.31
growth rate -7.3% 22.8% 19.6% 18.7%
Inventory 3.20
4.80
growth rate 10.7%
Cur.Liabilities 1,131.25
1,209.23
1,169.99
1,243.06
1,123.94
growth rate 6.9% -3.2% 6.2% -9.6%
Liabilities 1,289.46
1,327.48
1,280.24
1,354.18
1,585.37
growth rate 3.0% -3.6% 5.8% 17.1%
LT Debt 348.48
growth rate
Equity 1,618.06
1,513.85
1,578.48
1,711.12
1,850.24
growth rate -6.4% 4.3% 8.4% 8.1%
Common Shares 54.18
4.56
4.57
4.58
4.58
growth rate -91.6% 0.2% 0.2% 0.0%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 18.72
11.31
9.85
6.87
23.03
growth rate -39.6% -12.9% -30.3% 235.5%
Cash Dividends
growth rate
Cash From OA 134.45
142.76
117.89
111.97
195.42
growth rate 6.2% -17.4% -5.0% 74.5%
Sale Purchase of Stock -5.36
-175.00
0.00
0.00
growth rate 0.0% 0.0%
FCF 115.73
131.45
108.04
105.10
172.39
growth rate 13.6% -17.8% -2.7% 64.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 725.41
715.10
620.23
701.73
760.23
growth rate -1.4% -13.3% 13.1% 8.3%
Op.Income 115.33
106.29
75.04
108.40
119.86
growth rate -7.8% -29.4% 44.5% 10.6%
IBT 113.48
104.92
54.17
105.35
116.40
growth rate -7.5% -48.4% 94.5% 10.5%
Net Income 99.01
91.70
47.76
91.64
101.23
growth rate -7.4% -47.9% 91.9% 10.5%
EPS
growth rate
Gross Profit 217.22
210.51
174.40
208.32
225.48
growth rate -3.1% -17.2% 19.5% 8.2%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (83.82)

YOY Growth Grade:

C (55.29)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 33.06 32.21 22.27
EPS / Growth 16.1% 6.15 10.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 14.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 10.7% 13.6% 13.6%
Future PE 21.30 27.52 27.52
Future EPS 16.92 22.03 22.03
Value Price
MOS %
89.08
-55.0%
149.85
-24.3%
149.85
-24.3%
MOS Price 44.54 74.92 74.92
IRT 13.94 12.37 12.37

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.